Assignee
POXEL SA
FR·12 granted patents·7 pending applications·5 citations·filing 2017–2025
Top patents by PatentIndex Score
19 records- 0188US11123336B25-deutero-2,4-thiazolidinedione derivatives and compositions comprising and methods of using the samePOXEL SA·Filed 2019·Granted Sep 21, 2021·2 cites·21 claims
- 0285US10940143B2Deuterium-enriched pioglitazonePOXEL SA·Filed 2019·Granted Mar 9, 2021·1 cites·8 claims
- 0383US10265305B25-deutero-2,4-thiazolidinedione derivatives and compositions comprising and methods of using the samePOXEL SA·Filed 2017·Granted Apr 23, 2019·2 cites·9 claims
- 0478US11918569B25-deutero-2,4-thiazolidinedione derivatives and compositions comprising and methods of using the samePOXEL SA·Filed 2021·Granted Mar 5, 2024·0 cites·28 claims
- 0577US11918567B2Deuterium-enriched pioglitazonePOXEL SA·Filed 2021·Granted Mar 5, 2024·0 cites·9 claims
- 0676US2025268879A1Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazonePOXEL SA·Filed 2025·Application pending·0 cites
- 0773US11141411B2Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazonePOXEL SA·Filed 2018·Granted Oct 12, 2021·0 cites·18 claims
- 0873US2022193055A1Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazonePOXEL SA·Filed 2021·Application pending·0 cites
- 0968US10576071B2Deuterium-enriched pioglitazonePOXEL SA·Filed 2018·Granted Mar 3, 2020·0 cites·10 claims
- 1067US2022362220A15-deutero-thiazolidine-2,4-dione compounds and methods of treating medical disorders using samePOXEL SA·Filed 2020·Application pending·0 cites
- 1166US2020253937A15-deutero-thiazolidine-2,4-dione compounds and methods of treating medical disorders using samePOXEL SA·Filed 2019·Application pending·0 cites
- 1264US11319313B2Crystalline forms of deuterium-enriched pioglitazonePOXEL SA·Filed 2021·Granted May 3, 2022·0 cites·14 claims
- 1362US2023074827A1Crystalline forms of deuterium-enriched pioglitazonePOXEL SA·Filed 2022·Application pending·0 cites
- 1461US2020239457A15-deutero-thiazolidinyldione compounds and methods of treating medical disorders using samePOXEL SA·Filed 2019·Application pending·0 cites
- 1560US12036226B2Methods of treating subjects having diabetes with chronic kidney diseasePOXEL SA·Filed 2022·Granted Jul 16, 2024·0 cites·20 claims
- 1660US11617754B2Methods of treating heart failure with preserved ejection fractionPOXEL SA·Filed 2018·Granted Apr 4, 2023·0 cites·22 claims
- 1760US2020390753A1Combination therapy using enantiopure, oxy-substituted, deuterium-enriched 5-(benzyl)-5-deutero-thiazolidine-2,4-diones for treatment of medical disordersPOXEL SA·Filed 2019·Application pending·0 cites
- 1855US11767317B1Methods of synthesizing enantiopure deuterium-enriched pioglitazonePOXEL SA·Filed 2021·Granted Sep 26, 2023·0 cites·20 claims
- 1953US11266652B2Methods of treating subjects having diabetes with chronic kidney diseasePOXEL SA·Filed 2020·Granted Mar 8, 2022·0 cites·20 claims
Join the waitlist — get patent alerts
Get an alert when POXEL SA files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →